Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | DAD trial: combining sacituzumab govitecan and EV for the treatment of bladder cancer

Elizabeth R. Plimack • 22 Oct 2023
ESMO 2023
Bladder Cancer Urothelial Carcinoma Antibodies Enfortumab vedotin Sacituzumab govitecan

Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, discusses the Phase I DAD trial (NCT04724018) evaluating the efficacy and safety of sacituzumab govitecan and enfortumab vedotin, two antibody-drug conjugates, as a combination therapy for the treatment of metastatic bladder cancer. Dr Plimack also discusses the challenges associated with combination therapies.This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elizabeth R. Plimack

1:08
The role of molecular biomarkers in determining patient response to bladder cancer treatment
Elizabeth R. Plimack • 22 Oct 2023
1:05
The role of systemic therapy in the context of bladder preservation
Elizabeth R. Plimack • 22 Oct 2023

Related Videos

0:57
PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab
Jonathan Rosenberg • 7 Apr 2024
1:05
HRQoL in patients with previously treated advanced urothelial carcinoma from EV-301: EV vs chemo
Jonathan Rosenberg • 7 Apr 2024
1:07
Developing targeted therapies for urachal and non-urachal adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:21
Genomic differences between urachal and non-urachal bladder adenocarcinoma
Antonio Cigliola • 26 Jan 2024
The content of VJOncology is intended for healthcare professionals